{Reference Type}: Case Reports
{Title}: Case report and literature review of BRAF-V600 inhibitors for treatment of papillary craniopharyngiomas: A potential treatment paradigm shift.
{Author}: Nussbaum PE;Nussbaum LA;Torok CM;Patel PD;Yesavage TA;Nussbaum ES;
{Journal}: J Clin Pharm Ther
{Volume}: 47
{Issue}: 6
{Year}: Jun 2022
{Factor}: 2.145
{DOI}: 10.1111/jcpt.13600
{Abstract}: <B>OBJECTIVE: </B>The BRAF-V600E genetic mutation offers a potential targeted therapy for the treatment of papillary craniopharyngiomas.<BR><B>METHODS: </B>A 35-year-old man underwent a craniotomy and subtotal resection of a large BRAF-V600E-positive papillary craniopharyngioma before referral to our institution. Our treatment included the BRAF-V600 inhibitor dabrafenib mesylate (75 mg, twice/day) and trametinib dimethyl sulfoxide (2 mg/day). The residual tumour decreased in size by 95% over 21 months without negative side effects.<BR><B>CONCLUSIONS: </B>We reviewed the literature on BRAF-V600E inhibition as a non-invasive method of treating papillary craniopharyngiomas harbouring the BRAF-V600E mutation.